Regeneron Pharmaceuticals' Upcoming Investor Conferences
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is set to engage with investors through a series of important webcasts. These events will provide a platform for the company’s management to share insights and developments concerning their innovative therapies.
Conference Schedule Overview
The following conferences are on the horizon for Regeneron:
BofA Securities 2025 Health Care Conference
Scheduled for May 13, 2025, at 10:00 a.m. PT (1:00 p.m. ET), this conference aims to showcase Regeneron’s advancements and future prospects.
RBC Capital Markets Global Healthcare Conference
On May 20, 2025, at 11:00 a.m. ET, key executives from Regeneron will present at this influential conference, allowing investors to gain valuable insights into the company’s strategic directions.
Bernstein Annual Strategic Decisions Conference
Taking place on May 28, 2025, at 11:00 a.m. ET, this conference offers a unique opportunity for Regeneron to communicate its long-term vision and reinforce its commitment to medical innovation.
Goldman Sachs Annual Global Healthcare Conference
On June 9, 2025, at 10:40 a.m. ET, Regeneron will share its latest findings and development strategies, further solidifying its place in the biotechnology landscape.
How to Access the Webcasts
These sessions can be easily accessed from the 'Investors & Media' page on Regeneron’s official website. After each presentation, replays and transcripts will be made available for a minimum of 30 days, giving investors a chance to catch up on any missed content.
About Regeneron
Regeneron is a prominent biotechnology firm dedicated to inventing, developing, and bringing life-changing medicines to market. Since its inception, Regeneron has been spearheaded by physician-scientists who leverage their expertise to translate scientific knowledge into tangible healthcare solutions. The portfolio includes treatments targeting numerous serious diseases, reflecting the company’s broad commitment to improving health.
Boasting an impressive range of therapies and a pipeline of innovative product candidates, Regeneron focuses on various conditions including eye diseases, allergic and inflammatory disorders, cancers, cardiovascular issues, and genetic disorders. The company continually evolves by pushing the boundaries of scientific exploration and swiftly advancing drug development through proprietary technologies like the VelociSuite, which is instrumental in creating optimized fully human antibodies.
Regeneron’s Commitment to Innovation
At Regeneron, a data-driven approach is cultivated through the Regeneron Genetics Center, a platform that enables the identification of novel therapeutic targets. Through these advanced methods, Regeneron seeks to innovate in ways that may not only treat but potentially cure diseases, demonstrating their dedication to transforming patient care.
Stay Connected with Regeneron
For further updates on Regeneron’s conferences and innovative solutions, everyone is encouraged to visit the company's website at www.Regeneron.com. Engaging on social media such as LinkedIn, Instagram, Facebook, and X offers an additional avenue to stay informed about Regeneron's evolving contributions to biotechnology.
Contacting Regeneron
For inquiries, investors can reach out to:
Investor Relations
Ryan Crowe
914.847.8790
ryan.crowe@regeneron.com
Frequently Asked Questions
What is Regeneron Pharmaceuticals known for?
Regeneron is known for developing life-changing biotechnology solutions for serious illnesses, with numerous approved treatments and ongoing research.
How can I access the presentations from the conferences?
The webcasts from the conferences can be accessed via the 'Investors & Media' page on Regeneron’s website, with replays available for 30 days.
Who can I contact for investor relations at Regeneron?
For investor inquiries, you can contact Ryan Crowe at 914.847.8790 or via email at ryan.crowe@regeneron.com.
What types of diseases does Regeneron focus on?
Regeneron focuses on a wide range of diseases, including cancer, eye diseases, and various genetic disorders, among others.
What innovative technologies does Regeneron use?
Regeneron utilizes advanced technologies such as VelociSuite to develop fully human antibodies and explore novel therapeutic targets through genetic insights.
